Tag Archive for: Orphan diseases

In a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.

© Olga Yastremska, New Africa, freepik

Researchers developed an innovative ear transplant method to treat microtia using tissue-engineered human skin and bioprinted cartilage.